Cargando…
Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
Autores principales: | Nakamura, Ikuo, Zakharia, Kais, Banini, Bubu A., Mikhail, Dalia S., Kim, Tae Hyo, Yang, Ju Dong, Moser, Catherine D., Shaleh, Hassan M., Thornburgh, Sarah R., Walters, Ian, Roberts, Lewis R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631495/ https://www.ncbi.nlm.nih.gov/pubmed/26528545 http://dx.doi.org/10.1371/journal.pone.0142355 |
Ejemplares similares
-
Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
por: Nakamura, Ikuo, et al.
Publicado: (2014) -
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
por: Ballas, Marc S, et al.
Publicado: (2011) -
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
por: Madsen, Christine Vestergaard, et al.
Publicado: (2012) -
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
por: Jones, Robin L., et al.
Publicado: (2019) -
Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2023)